Expanded use and availability of medication-assisted treatment is a top priority of federal effort to combat opioid epidemic
Silver Spring, Maryland–(ENEWSPF)–May 26, 2016. The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a…
